Details for Patent: 9,018,210

Which drugs does patent 9,018,210 protect, and when does it expire?

Patent 9,018,210 protects OXBRYTA and is included in two NDAs.

This patent has seventy-five patent family members in thirty countries.

Summary for Patent: 9,018,210

Title:	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Abstract:	Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
Inventor(s):	Metcalf; Brian (Moraga, CA), Chuang; Chihyuan (Millbrae, CA)
Assignee:	Global Blood Therapeutics, Inc. (South San Francisco, CA) Cytokinetics, Inc. (South San Francisco, CA) The Regents of the University of California (Oakland, CA)
Application Number:	13/730,674
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 9,018,210

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Global Blood Theraps	OXBRYTA	voxelotor	TABLET, FOR SUSPENSION;ORAL	216157-001	Dec 17, 2021		RX	Yes	Yes			Y	Y
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-002	Oct 14, 2022		RX	Yes	No			Y	Y
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-001	Nov 25, 2019		RX	Yes	Yes			Y	Y

International Family Members for US Patent 9,018,210

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2797416		301191	Netherlands
European Patent Office	2797416		CA 2022 00032	Denmark
European Patent Office	2797416		PA2022517	Lithuania
European Patent Office	2797416		122022000052	Germany